Table of Contents 2
List of Tables 5
List of Figures 6
Report Guidance 7
GlobalData Clinical Trials Report Coverage 8
Clinical Trials by Region 9
Clinical Trials and Average Enrollment by Country 10
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13
Top Five Countries Contributing to Clinical Trials in Europe 14
Top Countries Contributing to Clinical Trials in North America 15
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 16
Top Five Countries Contributing to Clinical Trials in Central and South America 17
Clinical Trials by G7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 18
Clinical Trials by Phase in G7 Countries 20
Clinical Trials in G7 Countries by Trial Status 21
Clinical Trials by E7 Countries: Proportion of Non-Small Cell Lung Cancer to Oncology Clinical Trials 23
Clinical Trials by Phase in E7 Countries 25
Clinical Trials in E7 Countries by Trial Status 26
Clinical Trials by Phase 28
In Progress Trials by Phase 29
Clinical Trials by Trial Status 30
Clinical Trials by End Point Status 32
Subjects Recruited Over a Period of Time 33
Clinical Trials by Sponsor Type 34
Prominent Sponsors 35
Top Companies Participating in Non-Small Cell Lung Cancer Therapeutics Clinical Trials 37
Prominent Drugs 39
Latest Clinical Trials News on Non-Small Cell Lung Cancer 40
Apr 10, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA 40
Apr 10, 2018: Spectrum Pharmaceuticals Announces Update of MD Anderson’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients 40
Apr 09, 2018: NICE gives Green Light to New Immunotherapy for most Common form of Lung Cancer 40
Apr 09, 2018: KEYTRUDA (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells 41
Apr 09, 2018: G1 Therapeutics to Present Preclinical Data on G1T38 at the 2018 American Association for Cancer Research (AACR) Annual Meeting 41
Apr 05, 2018: Molecular Partners to present MP0310 pre-clinical data at the AACR Annual Meeting 2018 42
Apr 05, 2018: Molecular Partners to present MP0250 clinical abstract at the AACR Annual Meeting 2018 42
Apr 04, 2018: Loxo Oncology Announces Acceptance of LOXO-292 Oral Presentation at the American Society of Clinical Oncology Annual Meeting 42
Apr 04, 2018: Vaccibody as Announces Informed Consent Signed by First Patient and Enrollment Process Initiated in the Cancer Neoantigen Phase I/IIA Clinical Trial 43
Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer 43
Mar 22, 2018: BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe 44
Mar 22, 2018: Oncology Venture Sweden: Scientific Journal Highlights Study Of The Drp Tool In Cisplatin Treatment For Patients With Lung Cancer 44
Mar 19, 2018: Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Squamous Lung Cancer 45
Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment 46
Mar 14, 2018: Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018 46
Mar 14, 2018: First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting 46
Mar 14, 2018: TESARO to Present Data on Oncology Product Candidate TSR-042 at AACR 2018 Annual Meeting 48
Mar 14, 2018: Research from Bristol-Myers Squibb’s Innovative Oncology Development Program to Be Presented at AACR 2018 Demonstrates Commitment to Advancing Precision Medicine Research for Patients with Cancer 48
Mar 12, 2018: AstraZeneca Provides Update on MYSTIC Trial Timeline 50
Mar 12, 2018: Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer 50
Feb 28, 2018: Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer 51
Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment 51
Feb 23, 2018: L-DOS47 US Phase I Study Presentation at the IASLC 18th Annual Target Therapies of Lung Cancer Meeting 51
Feb 22, 2018: Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer 52
Feb 15, 2018: Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer 52
Feb 14, 2018: Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond 53
Feb 13, 2018: Chi-Med Completes Enrollment of 527 Patients in Pivotal Phase III FALUCA Trial with Fruquintinib in Lung Cancer 53
Feb 07, 2018: Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer 54
Feb 07, 2018: Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations 55
Feb 05, 2018: Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients with High Tumor Mutation Burden 55
Jan 31, 2018: Puma Biotechnology Announces Publication of Results from Phase II SUMMIT ‘Basket’ Trial Evaluating Neratinib in HER2 and HER3 Mutant Cancer 56
Jan 30, 2018: Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study 56
Jan 23, 2018: Biomarck Announces the Start of a Phase 2 Clinical Trial of BIO-11006 for Non-Small Cell Lung Cancer 57
Jan 16, 2018: First Patient Dosed in a Phase 2 Trial with Transgene TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC) 57
Jan 16, 2018: Merck’s KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (KEYNOTE-189) 58
Clinical Trial Profile Snapshots 59
Appendix 3966
Abbreviations 3966
Definitions 3966
Research Methodology 3967
Secondary Research 3967
About GlobalData 3968
Contact Us 3968
Disclaimer 3968
Source 3969
